215 related articles for article (PubMed ID: 35418378)
1. Teprotumumab-associated chronic hearing loss screening and proposed treatments.
Chow A; Silkiss RZ
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35418378
[TBL] [Abstract][Full Text] [Related]
2. Ototoxicity and Teprotumumab.
Highland J; Gordon S; Reddy D; Patel N
Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414
[TBL] [Abstract][Full Text] [Related]
3. Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.
Phansalkar R; Lu T; Alyono J; Lee J; Dosiou C; Kossler AL
Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):e101-e104. PubMed ID: 36877549
[TBL] [Abstract][Full Text] [Related]
4. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
Ding AS; Mahoney NR; Campbell AA; Creighton FX
Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
[TBL] [Abstract][Full Text] [Related]
5. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
6. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease.
Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD
Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314
[TBL] [Abstract][Full Text] [Related]
7. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
[TBL] [Abstract][Full Text] [Related]
8. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
[TBL] [Abstract][Full Text] [Related]
9. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
Chern A; Dagi Glass LR; Gudis DA
Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
[TBL] [Abstract][Full Text] [Related]
10. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
[TBL] [Abstract][Full Text] [Related]
12. Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring.
Belinsky I; Creighton FX; Mahoney N; Petris CK; Callahan AB; Campbell AA; Kazim M; Lee HBH; Yoon MK; Dagi Glass LR
Ophthalmic Plast Reconstr Surg; 2022 Jan-Feb 01; 38(1):73-78. PubMed ID: 34085994
[TBL] [Abstract][Full Text] [Related]
13. Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report.
Lu TJ; Amarikwa L; Winn BJ; Inserra M; Dosiou C; Kossler AL
Case Rep Ophthalmol; 2023; 14(1):134-139. PubMed ID: 37034380
[TBL] [Abstract][Full Text] [Related]
14. Teprotumumab for the treatment of thyroid eye disease.
Ju Y; Yang J
Expert Rev Clin Immunol; 2020 Aug; 16(8):739-743. PubMed ID: 32707005
[TBL] [Abstract][Full Text] [Related]
15. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.
Chu M; Sung J; Song M; Song A; Song J
J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553
[TBL] [Abstract][Full Text] [Related]
16. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
Winn BJ; Kersten RC
Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
[TBL] [Abstract][Full Text] [Related]
17. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
[TBL] [Abstract][Full Text] [Related]
18. Successful Case of Teprotumumab Treatment in an Adolescent Patient With Thyroid Eye Disease.
Radulovich N; Van Brummen A; Chambers C; Zhang M
Ophthalmic Plast Reconstr Surg; 2024 Mar-Apr 01; 40(2):e65-e67. PubMed ID: 38231594
[TBL] [Abstract][Full Text] [Related]
19. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
Shah SA; Amarikwa L; Sears CM; Clauss KD; Rajjoub RD; Kang JY; Tamhankar MA; Briceño CA; Harrison AR; Dosiou C; Cockerham KP; Wester ST; Douglas RS; Kossler AL
Ophthalmology; 2024 Apr; 131(4):458-467. PubMed ID: 37852417
[TBL] [Abstract][Full Text] [Related]
20. Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison.
Douglas RS; Dailey R; Subramanian PS; Barbesino G; Ugradar S; Batten R; Qadeer RA; Cameron C
JAMA Ophthalmol; 2022 Apr; 140(4):328-335. PubMed ID: 35175308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
